Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Ebola virus vaccine industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Strain type trends
2.1.4 End-use trends
Chapter 3 Ebola Virus Vaccine Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of zoonotic disease
3.2.1.2 Increasing R&D for Ebola virus vaccines development
3.2.1.3 Growing focus on preventive healthcare and pandemic preparedness
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory approval
3.3 Growth potential analysis
3.3.1 By strain type
3.3.2 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategy outlook matrix
Chapter 5 Ebola Virus Vaccine Market Size and Forecast, By Strain Type (USD Million)
5.1 Key trends, by strain type
5.2 Vesicular Stomatitis Virus (rVSV)
5.3 Adeno Virus Serotype - 26
Chapter 6 Ebola Virus Vaccine Market Size and Forecast, By End-use (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals
6.3 Clinics
6.4 Ambulatory Surgical Centers
6.5 Other end-users
Chapter 7 Ebola Virus Vaccine Market Size and Forecast, By Region (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 Spain
7.3.4 Italy
7.3.5 Rest of Europe
7.4 Africa
7.4.1 The Democratic Republic of the Congo (DRC)
7.4.2 Burundi
7.4.3 Ghana
7.4.4 Zambia
Chapter 8 Company Profiles
8.1 Merck & Co., Inc
8.2 Johnson & Johnson Private Limited
8.3 GlaxoSmithKline plc
8.4 Bavarian Nordic
8.5 Emergent BioSolutions Inc.
8.6 Novavax, Inc
8.7 Nanoviricides, INC
8.8 BioCryst Pharmaceuticals, Inc.
8.9 GeoVax
8.10 Mapp Biopharmaceutical
